Navigation Links
Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Date:8/28/2008

OSLO, August 28 /PRNewswire-FirstCall/ --

- Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC)

Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain palliation study was met. The study showed that even single doses of Alpharadin in patients with painful bone metastases could produce increasing clinical benefit with increasing dose. Pain palliation is an important quality of life benefit in metastatic cancer patients. The trial also confirmed Alpharadin's benign side-effect profile and, importantly for a drug in this clinical setting, no significant bone marrow toxicity was observed.

In men with HRPC life expectancy can be as short as 18 months, and it is estimated that 100,000 men in the EU and USA die from the disease each year. In 85% of these men the tumor will have spread into the bones. These metastases are a significant problem as they can cause intractable and debilitating pain as well as contributing to a further reduction in life expectancy.

The BC1-03 study was a double-blind randomised pain control study comparing the palliative effects of four different single dose levels of Alpharadin in patients with bony metastatic HRPC. The drug was given by i.v. injection mainly on an outpatient basis. The palliative efficacy of Alpharadin was measured using an assessment of bone pain as well as the patient's consumption of analgesia. The primary study objective was to investigate whether there was a dose-response relationship with respect to pain palliation in this patient group. The study has shown the beneficial palliative effect of a single dose of Alpharadin and that there is a clear dose-response effect, with higher doses providing better pain relief.

The study also showed a dose-dependent reduction in bone al
'/>"/>

SOURCE Algeta
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
2. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
3. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
4. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
5. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
6. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
8. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
9. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
10. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
11. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) ... of schizophrenia and manic or mixed episodes associated with ... ,, The updated Zyprexa label states that clinicians ... gain and hyperlipidemia in adolescents compared to adults and ...
(Date:12/4/2009)... (Pink Sheets: VRMLQ) announced that on December 3, 2009, it ... Disclosure Statement with the United States Bankruptcy Court for the ... the adequacy of the Disclosure Statement is presently scheduled for ... the Plan scheduled for January 7, 2010. ,, "We are ...
(Date:12/4/2009)... Dec. 4 Amber Pharmacy announced today that it ... Inc. (ACHC) for specialized pharmacy services. For nearly 15 ... and services to meet the unique needs of specialized ... of services to transplant programs. They work with over ...
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Amber Pharmacy Earns Accreditation From ACHC 2STEMCELL Technologies Inc Announces Direct Distribution to Spain 59120 1STEMCELL Technologies Inc Announces Direct Distribution to Spain 59120 2STEMCELL Technologies Inc Announces Direct Distribution to Spain 59120 3STEMCELL Technologies Inc Announces Direct Distribution to Spain 59120 4Purity Products Releases Their Brand New Mediterranean Diet Resveratrol Formula 59118 1Purity Products Releases Their Brand New Mediterranean Diet Resveratrol Formula 59118 2Chronic Fatigue Syndrome and Stem Cell Therapy Latest Research Available at CheneyResearch com 59116 1Chronic Fatigue Syndrome and Stem Cell Therapy Latest Research Available at CheneyResearch com 59116 2Chronic Fatigue Syndrome and Stem Cell Therapy Latest Research Available at CheneyResearch com 59116 3
... AACR Meeting Highlights Potential Therapeutic Approach to Treat ... Micromet, Inc. (Nasdaq: MITI ), ... the treatment of cancer, inflammation and autoimmune diseases, ... of the American Association for Cancer Research (AACR). ...
... for Cancer Research -PRINCETON, N.J., April 21 ... announced preclinical efficacy and safety data from multiple ... cancer targets (CXCR4, fucosyl-GM1, glypican-3, mesothelin, CD70) and ... Data from the studies were presented at the ...
Other Medicine Technology:Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells 2Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells 3Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells 4Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 2Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 3Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 4
(Date:12/6/2009)... researchers from the Medical College of Wisconsin, in Milwaukee, ... and other sickle cell disease complications in children. Barriers ... and patients were also identified. The study led ... pediatrics at the Medical College and Children,s Research Institute ... at the American Society of Hematology meeting Dec. 7, ...
(Date:12/6/2009)... site www.sleeping-with-a-sleeping-disorder.com is asking people ,who ... sleep aids from around the world to donate ... The submissions will be compiled in an ebook ... to be sold from the website in early ... the proceeds ,from sales of the E-book to ...
(Date:12/5/2009)... Cuts for a Cause ,, Why: To ... terminal illnesses affecting children. All proceeds from each hair service ... Guests will enjoy complimentary beverages and hors d,oeuvres, provided by ... Church for all guests. Hoa Lai, a DJ known for ...
(Date:12/5/2009)... being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- ... without ever tying the knot, since research has shown that ... um, isn,t there something wrong with those who go it ... looking at psychological measures shows that never-married people aged 40 ...
(Date:12/4/2009)... Systems (NYSE: VAR ) announced today that its ... of Stockholders for February 11, 2010 with a record date ... the Crowne Plaza Cabana Hotel, 4290 El Camino Real, Palo ... be webcast by Thomson Financial and can be accessed at ...
Breaking Medicine News(10 mins):Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2
... by 50%, study concludes, , , MONDAY, April 7 ... offer nutrition education and reward students for nutritious ... preventing childhood obesity, according to a Temple University ... multifaceted nutrition program reduced the number of overweight ...
... science education, scientific research, and the role science should play in ... ... NEW YORK, April 7, 2008 Since its launch in October,2006, the ... human health issues facing the 21st century, including the,brain, the human genome, ...
... Schizophrenia is a complex type of psychotic mental ... Huge gains in the effective treatment of individuals with ... of the first generation of antipsychotic drugs. The medications ... illness (delusions and hallucinations) and, to a lesser extent, ...
... SCRANTON, Pa., April 7, 2008 Penn Foster ... build essential skills,for working professionals. The program offerings ... -- Anatomy and Physiology, This broad ... working adults in,the health professions. Prospective nurses, medical ...
... is high in the antioxidant EGCG (epigallocatechin-3- gallate) which ... prematurely aged. Studies have suggested that the combination of ... providing protection against certain types of cancers, including breast ... University of Mississippi researchers now finds that consuming EGCG ...
... Enjoy His Young Family,and Active Life, MIDDLE ISLAND, ... Trade Center on September 11, 2001, New York,City Patrolman ... Now,more than seven years later, O,Connor needs help overcoming ... later in,the line of duty., At 32, Mr. ...
Other Medicine News:Health News:School Environment Can Curb Kids' Weight Gain 2Health News:Charlie Rose Science Series Wraps Up With Episode on 'The Imperative and Promise of Science' 2Health News:Charlie Rose Science Series Wraps Up With Episode on 'The Imperative and Promise of Science' 3Health News:Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected 2Health News:Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected 3Health News:Penn Foster Career School Offers Certificate Programs 2Health News:Ingredient found in green tea significantly inhibits breast cancer growth in female mice 2Health News:The SCOOTER Store Donates Power Scooter to Former NYPD Officer Who Responded to 9/11 2Health News:The SCOOTER Store Donates Power Scooter to Former NYPD Officer Who Responded to 9/11 3
Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
... As a pioneer in the design and ... extraction of viscous fluids, D.O.R.C. is pleased ... combination of injection and extraction in one ... controlled injection of viscous fluids, such as ...
... Wash both 96- and 384-well plates ... Strip Washer. As a self contained ... for full control of precise fluidic ... a simple squeeze bottle to the ...
The EL401 Manual Plate/Strip Washer accommodates all 96-well microplates and microwell strips. The unique alignment mechanism allows quick and accurate positioning of the 8- or 12-channel manifold ab...
Medicine Products: